215 related articles for article (PubMed ID: 36520493)
1. Hyperstabilization of T cell microvilli contacts by chimeric antigen receptors.
Beppler C; Eichorst J; Marchuk K; Cai E; Castellanos CA; Sriram V; Roybal KT; Krummel MF
J Cell Biol; 2023 Mar; 222(3):. PubMed ID: 36520493
[TBL] [Abstract][Full Text] [Related]
2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
3. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.
Wu L; Wei Q; Brzostek J; Gascoigne NRJ
Cell Mol Immunol; 2020 Jun; 17(6):600-612. PubMed ID: 32451454
[TBL] [Abstract][Full Text] [Related]
4. Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells.
Zheng R; Chen Y; Zhang Y; Liang S; Zhao X; Wang Y; Wang P; Meng R; Yang A; Yan B
Front Immunol; 2023; 14():1258156. PubMed ID: 38022548
[TBL] [Abstract][Full Text] [Related]
5. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.
Duan Y; Chen R; Huang Y; Meng X; Chen J; Liao C; Tang Y; Zhou C; Gao X; Sun J
Cell Mol Life Sci; 2021 Dec; 79(1):14. PubMed ID: 34966954
[TBL] [Abstract][Full Text] [Related]
6. Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.
Harris DT; Hager MV; Smith SN; Cai Q; Stone JD; Kruger P; Lever M; Dushek O; Schmitt TM; Greenberg PD; Kranz DM
J Immunol; 2018 Feb; 200(3):1088-1100. PubMed ID: 29288199
[TBL] [Abstract][Full Text] [Related]
7. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC; Riddell SR
Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
[TBL] [Abstract][Full Text] [Related]
8. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".
Teppert K; Wang X; Anders K; Evaristo C; Lock D; Künkele A
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498890
[TBL] [Abstract][Full Text] [Related]
9. From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.
Wu Y; Jiang S; Ying T
Expert Opin Biol Ther; 2016 Dec; 16(12):1469-1478. PubMed ID: 27618260
[TBL] [Abstract][Full Text] [Related]
10. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Lam N; Trinklein ND; Buelow B; Patterson GH; Ojha N; Kochenderfer JN
Nat Commun; 2020 Jan; 11(1):283. PubMed ID: 31941907
[TBL] [Abstract][Full Text] [Related]
11. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
12. A TCR-based Chimeric Antigen Receptor.
Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
Front Immunol; 2018; 9():2359. PubMed ID: 30369931
[TBL] [Abstract][Full Text] [Related]
14. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
15. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Fujiwara K; Masutani M; Tachibana M; Okada N
Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
[TBL] [Abstract][Full Text] [Related]
16. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
Akatsuka Y
Front Immunol; 2020; 11():257. PubMed ID: 32184779
[TBL] [Abstract][Full Text] [Related]
17. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering.
Si K; Dai Z; Li Z; Ye Z; Ding B; Feng S; Sun B; Shen Y; Xiao Z
Cytotherapy; 2023 Jun; 25(6):615-624. PubMed ID: 36828738
[TBL] [Abstract][Full Text] [Related]
18. T cells use distinct topographical and membrane receptor scanning strategies that individually coalesce during receptor recognition.
Cai E; Beppler C; Eichorst J; Marchuk K; Eastman SW; Krummel MF
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2203247119. PubMed ID: 35914144
[TBL] [Abstract][Full Text] [Related]
19. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
[TBL] [Abstract][Full Text] [Related]
20. Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity.
Vander Mause ER; Atanackovic D; Lim CS; Luetkens T
Trends Biotechnol; 2022 Jul; 40(7):875-890. PubMed ID: 35078657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
